💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for NMP

No earnings history available for this symbol.

📰 Related News & Research

• NMP Acquisition Corp. Issues 2025 PFIC Annual Statement for U.S. Shareholders and QEF Election Guidance
  April 4, 2026
  

  NMP Acquisition Corp. Releases PFIC Annual Statement: Key In...

• Anterix Inc. Files 8-K Announcing New Contract and Press Release with TNMP on Nasdaq Capital Market
  April 1, 2026
  

  Anterix Inc. Announces Spectrum Sale Agreement with Texas-Ne...

• Livzon Receives NMPA Approval for Clinical Trials of Brexpiprazole Microspheres for Schizophrenia Treatment in China
  March 27, 2026
  

  Livzon Pharmaceutical Group Receives Clinical Trial Approval...

• Lee’s Pharmaceutical Receives NMPA Approval for Intrarosa to Treat Vulvovaginal Atrophy in Postmenopausal Women 1
  March 26, 2026
  

  Lee’s Pharmaceutical Gains NMPA Approval for Intrarosa ...

• Hansoh Pharmaceutical Receives NMPA Approval for HS-20152 Injection Clinical Trials for Paroxysmal Nocturnal Hemoglobinuria 1
  March 23, 2026
  

  Hansoh Pharmaceutical Receives NMPA Approval for HS-20152 In...

• Hansoh Pharmaceutical Receives NMPA Clinical Trial Approval for HS-10587 Tablets Targeting MTAP-Deleted Advanced Solid Tumors 1
  March 23, 2026
  

  Hansoh Pharmaceutical Receives Clinical Trial Approval for H...

• NMP Acquisition Corp. 2025 Annual Report: Business Overview, Acquisition Strategies, Risks, and Financial Statements
  March 21, 2026
  

  NMP Acquisition Corp. 2025 Annual Report: Key Highlights and...

• Shanghai Henlius Biotech Receives NMPA Approval for Phase 1 Clinical Trial of Nivolumab Biosimilar HLX18 for Multiple Solid Tumors
  March 20, 2026
  

  Shanghai Henlius Biotech Announces IND Approval for Nivoluma...

• Sino Biopharmaceutical Gains NMPA Approval for TRD221 Clinical Trial Targeting Osteoarthritis Treatment 1
  March 17, 2026
  

  Sino Biopharmaceutical: Clinical Trial Approval for TRD221 C...

• Hangzhou Jiuyuan Genetic Biopharmaceutical Receives NMPA Approval for JY47 Injection Clinical Trial Targeting MASH with Liver Fibrosis
  March 17, 2026
  

  JY47 Injection Receives IND Approval – Key Developments for ...

🔍 View more Reports